Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/35243
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLamberti, Ángela-
dc.contributor.authorSERAFINI, MARTA-
dc.contributor.authorAprile, Silvio-
dc.contributor.authorPreet Bhela, Irene-
dc.contributor.authorGoutsiou, Georgia-
dc.contributor.authorPessolano, Emanuela-
dc.contributor.authorFernández Ballester, Gregorio-
dc.contributor.authorFerrer-Montiel, Antonio-
dc.contributor.authorDi Martino, Rita Maria Concetta-
dc.contributor.authorFernandez-Carvajal, Asia-
dc.contributor.authorPIRALI, Tracey-
dc.contributor.otherDepartamentos de la UMH::Bioquímica y Biología Moleculares_ES
dc.date.accessioned2025-01-24T12:43:02Z-
dc.date.available2025-01-24T12:43:02Z-
dc.date.created2024-12-
dc.identifier.citationEuropean Journal of Medicinal Chemistry Volume 279, 5 December 2024, 116845es_ES
dc.identifier.issn1768-3254-
dc.identifier.issn0223-5234-
dc.identifier.urihttps://hdl.handle.net/11000/35243-
dc.description.abstractA growing body of evidence points to the existence of a crosstalk between the endovanilloid (EV)- and the endocannabinoid (EC) systems, leading to the concept of a single system based on a shared set of endogenous ligands and regulation mechanisms. The EV/EC system encompasses the ion channel TRPV1, the G protein coupled receptors CB1 and CB2, their endogenous ligands and the enzymes for biosynthesis and inactivation. Disorders in which the EV/EC interaction is involved are inflammation, pain, neurodegenerative diseases and disorders of bones and skin. In the present paper, with the aim of targeting the EV/EC system, the Passerini reaction is used in a diversityoriented approach to generate a series of α-acyloxycarboxamides bearing different substructures that resemble endogenous ligands. Compounds have been screened for activity on TRPV1, CB1 and CB2 and metabolic stability in skin cells, liver subcellular fractions and plasma. This protocol allowed to generate agents characterized by a diverse activity on TRPV1, CB1 and CB2, as well as heterogeneous metabolic stability that could allow different routes of administration, from soft drugs for topical treatment of skin diseases to hard drugs for systemic use in inflammation and pain. Compared to natural mediators, these compounds have a better drug-likeness. Among them, 41 stands out as an agonist endowed with a well-balanced activity on both TRPV1 and CB2, high selectivity over TRPM8, TRPA1 and CB1, metabolic stability and synthetic accessibility.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent21es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectTRPV1 channeles_ES
dc.subjectCB receptorses_ES
dc.subjectPasserini multicomponent reactiones_ES
dc.subjectSoft druges_ES
dc.subjectDual targetinges_ES
dc.subjectPolipharmacologyes_ES
dc.subject.otherCDU::5 - Ciencias puras y naturales::57 - Biologíaes_ES
dc.titleThe multicomponent Passerini reaction as a means of accessing diversity in structure, activity and properties: Soft and hard vanilloid/cannabinoid modulatorses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.ejmech.2024.116845es_ES
Appears in Collections:
Artículos Bioquímica y Biología Molecular


Thumbnail

View/Open:
 1-s2.0-S0223523424007268-main.pdf

5,79 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???